Li-Qiang Meng
Overview
Explore the profile of Li-Qiang Meng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shu Y, Huang J, Zhang Y, Wang F, Wang X, Meng L, et al.
BMC Nephrol
. 2025 Feb;
26(1):71.
PMID: 39934691
Background: Relapse of membranous nephropathy (MN) and other glomerular diseases has been observed after COVID-19 infection. The risk factors contributing to disease progression in MN patients after contracting COVID-19 remain...
2.
Cheng Y, Zhu T, Ma Y, Ding Y, Meng L, Xue L, et al.
Zhen Ci Yan Jiu
. 2023 Sep;
48(9):914-22.
PMID: 37730262
Objective: To observe the anti-tumor effect of moxibustion with seed-sized moxa cones on Hepa1-6 liver cancer bearing (HLCB) mice and its regulatory mechanism on cell apoptosis. Methods: A total of...
3.
Lai X, Cui Z, Zhang H, Zhang Y, Wang F, Wang X, et al.
Int Urol Nephrol
. 2023 Jan;
55(6):1565-1574.
PMID: 36648742
Purpose: It is unclear whether long-term variability in low-density lipoprotein cholesterol (LDL-C) is associated with clinical outcomes in patients with nephrotic syndrome (NS). Methods: A large cohort of 1100 patients...
4.
Lai X, Cui Z, Zhang H, Zhang Y, Wang F, Wang X, et al.
Ren Fail
. 2022 Nov;
44(1):1915-1923.
PMID: 36369936
Background: Patients with persistent nephrotic-range proteinuria have a high risk of kidney dysfunction and cardiovascular events. Recently, the maintenance of proteinuria remission has been demonstrated to reduce the risk of...
5.
Cheng Y, Cheng X, Zhang Y, Wang F, Wang X, Meng L, et al.
J Nephrol
. 2021 Nov;
35(4):1145-1157.
PMID: 34846713
Background: Many patients with primary membranous nephropathy have severe proteinuria unresponsive to optimized renin-angiotensin-aldosterone system inhibitors (RAASi). We evaluated the efficacy and safety of hydroxychloroquine as an adjunctive agent in...
6.
Gao S, Cui Z, Wang X, Zhang Y, Wang F, Cheng X, et al.
Front Med (Lausanne)
. 2021 Jun;
8:663680.
PMID: 34095173
Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN). We retrospectively reviewed 95 patients with pMN who received rituximab therapy...
7.
Huang J, Cui Z, Gu Q, Zhang Y, Qu Z, Wang X, et al.
PLoS One
. 2020 Jun;
15(6):e0234934.
PMID: 32569286
Background: Studies on adriamycin mice model suggest complement system is activated and together with IgM contributes to the glomerular injury of primary focal segmental glomerulosclerosis (FSGS). We recently reported primary...
8.
Liu Z, Cui Z, He Y, Zhang Y, Wang F, Wang X, et al.
Am J Nephrol
. 2020 Feb;
51(4):304-317.
PMID: 32097941
Background: Primary membranous nephropathy (pMN) is less common in women of child-bearing age. The kidney risk factors to adverse maternal-fetal outcomes and the effects of pregnancy on pMN process need...
9.
Zhang M, Huang J, Zhang Y, Qu Z, Wang X, Wang F, et al.
BMC Nephrol
. 2019 Aug;
20(1):313.
PMID: 31399080
Background: Complement activation plays a substantial role in the pathogenesis of primary membranous nephropathy (pMN). C5b-9, C3c, MBL, and factor B have been documented in the subepithelial immune deposits. However,...
10.
Qu Z, Zhang M, Cui Z, Wang J, Wang M, Zhang Y, et al.
Am J Nephrol
. 2018 Nov;
48(6):438-446.
PMID: 30472708
Background: Anti-phospholipase A2 receptor (PLA2R) antibodies are specific to the diagnosis of primary membranous nephropathy (pMN). The prevalence of positive antibodies varies among different cohorts. Still there is discrepancy in...